

9. (amended) A method of enhancing the cytotoxic effect of TNF $\alpha$ , comprising administering a therapeutically effective amount of an NF- $\kappa$ B inhibitor in conjunction with the intratumoral administration of TNF $\alpha$ , whereby the cytotoxic effect of TNF $\alpha$  is increased compared to that which would occur in the absence of said NF- $\kappa$ B inhibitor.

10. (amended) A method according to claim 9 wherein said NF- $\kappa$ B inhibitor is administered simultaneously with said TNF $\alpha$ .

11. (amended) A method of enhancing chemotherapeutic cytotoxicity in a subject treated with intratumoral TNF $\alpha$ , comprising administering to the subject a therapeutically effective amount of NF- $\kappa$ B inhibitor in conjunction with the administration of TNF $\alpha$ , whereby the cytotoxic effect of said TNF $\alpha$  is increased compared to that which would occur in the absence of NF- $\kappa$ B inhibitor.

12. (amended) A method according to claim 11 wherein said NF- $\kappa$ B inhibitor is administered simultaneously with said TNF $\alpha$ .

**Please add the following claims:**

*B4*  
14. A method of treating a tumor with a chemotherapeutic agent, the improvement comprising administering an effective amount of an NF- $\kappa$ B inhibitor in conjunction with said chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of said NF- $\kappa$ B inhibitor.

*MM*  
15. A method of treating a subject receiving a chemotherapeutic agent for the treatment of a neoplastic growth, the improvement comprising administering an effective amount of an NF- $\kappa$ B inhibitor to the subject in conjunction with said chemotherapeutic agent, wherein the effect is to increase the cytotoxic effects of said chemotherapeutic agent.

*B4  
Conc*

16. A method of increasing the cytotoxicity of a chemotherapeutic drug administered to a subject for the treatment of a neoplastic growth, comprising administering an effective amount of an NF- $\kappa$ B inhibitor to said subject in conjunction with said chemotherapeutic drug, wherein the effect is to increase the cytotoxic effects of said chemotherapeutic drug.

17. The method of claim 1 where said chemotherapeutic agent is irinotecan.

18. A method according to claim 1 wherein said NF- $\kappa$ B inhibitor is the super-repressor I $\kappa$ B $\alpha$ .

19. The method of claim 6 where said chemotherapeutic agent is irinotecan.

20. A method according to claim 6 wherein said NF- $\kappa$ B inhibitor is the super-repressor I $\kappa$ B $\alpha$ .

21. The method of claim 14 where said chemotherapeutic agent is irinotecan.

22. A method according to claim 14 wherein said NF- $\kappa$ B inhibitor is the super-repressor I $\kappa$ B $\alpha$ .

23. The method of claim 15 where said chemotherapeutic agent is irinotecan

24. A method according to claim 15 wherein said NF- $\kappa$ B inhibitor is the super-repressor I $\kappa$ B $\alpha$ .

25. The method of claim 16 where said chemotherapeutic agent is irinotecan.

*B3  
Conc*